PRRT genomic signature in blood for prediction of ¹⁷⁷Lu-octreotate efficacy.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ) which stratifies PRRT "responders" from "non-responders". This study clinically validates the utility of the PPQ in NETs.

Methods

The development and validation of the PPQ was undertaken in three independent ¹⁷⁷Lu-PRRT treated cohorts. Specificity was tested in two separate somatostatin analog-treated cohorts. Progno

SUBMITTER: Bodei L 

PROVIDER: S-EPMC6716527 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature